Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Agenus Inc (AGEN)

Agenus Inc (AGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Agenus Announces the Appointment of Dr. Jennifer Buell to the position of President and COO

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, is pleased to announce the appointment of Dr. Jennifer Buell to President...

AGEN : 3.99 (+2.31%)
Agenus Initiates Phase I Study on Oncology Candidate AGEN1223

Agenus (AGEN) initiates phase I study on AGEN1223, a novel bi-specific antibody designed to deplete regulatory T cells in the tumor micro environment.

EBS : 58.60 (+2.23%)
AGEN : 3.99 (+2.31%)
GILD : 63.37 (+1.18%)
BOLD : 59.97 (-0.02%)
Biotechnological Breakthroughs Help Revamp the Fight Against Cancer

Biotechnology plays an important role throughout various sectors by improving industry standards, services, and developing new products. While agriculture, material science and environmental science are...

TOMDF : 0.0299 (-12.06%)
AGEN : 3.99 (+2.31%)
LPTX : 1.82 (-2.67%)
TRIL : 3.20 (+15.52%)
VSTM : 1.92 (+7.26%)
Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease

Amicus (FOLD) announces updates on its investigational therapy, AT-GAA, for Pompe disease.

AMRN : 20.77 (-1.42%)
FOLD : 9.69 (-0.92%)
AGEN : 3.99 (+2.31%)
AQB : 2.22 (+2.30%)
Agenus Commences Phase 1 trial with AGEN1223

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, announced the dosing of the first patient with AGEN1223. AGEN1223 is...

AGEN : 3.99 (+2.31%)
Innate Pharma's Filing for Leukemia Drug Accepted in Europe

The EMA accepts Innate's (IPHA) marketing application for Lumoxiti, developed to treat relapsed/refractory hairy cell leukemia in adult patients having received minimum two prior systemic therapies.

AZN : 50.36 (-0.87%)
AGEN : 3.99 (+2.31%)
NCNA : 5.17 (+0.29%)
IPHA : 7.60 (+1.20%)
Pulmatrix Surges on License Agreement With Johnson & Johnson

Pulmatrix (PULM) inks an agreement with an entity of J&J, granting it the license to develop a portfolio of narrow spectrum kinase inhibitors for lung cancer interception.

JNJ : 148.36 (-0.61%)
CHRS : 19.00 (-1.45%)
PULM : 1.57 (-2.48%)
AGEN : 3.99 (+2.31%)
Amicus Progresses on Pipeline Development Amid Competition

Amicus (FOLD) progresses with the development of its pipeline. However, the company faces substantial competition.

SNY : 49.43 (-1.55%)
FOLD : 9.69 (-0.92%)
ALXN : 111.22 (-1.58%)
AGEN : 3.99 (+2.31%)
Arena (ARNA) Expands Strategic Deal With Beacon Discovery

Arena (ARNA) enters into multi-year strategic partnership with Beacon Discovery to discover and develop therapies targeting multiple immune and inflammatory indications.

CHRS : 19.00 (-1.45%)
AGEN : 3.99 (+2.31%)
ARNA : 45.78 (+0.79%)
UTHR : 91.98 (+0.11%)
Agenus Commences Combination Trial of its Next-Gen CTLA-4 with its PD-1 Antibody

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, today announced the first patient dosed with...

AGEN : 3.99 (+2.31%)
Agenus Inc Set to Possibly Rebound After Yesterday's Selloff of 4.95%

Agenus Inc (NASDAQ:AGEN) traded in a range yesterday that spanned from a low of $3.65 to a high of $3.86. Yesterday, the shares fell 4.9%, which took the trading range below the 3-day low of $3.75 on...

AGEN : 3.99 (+2.31%)
All You Need to Know About Agenus (AGEN) Rating Upgrade to Buy

Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AGEN : 3.99 (+2.31%)
Agenus (AGEN) Up 24.5% Since Last Earnings Report: Can It Continue?

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AGEN : 3.99 (+2.31%)
Watch for Agenus Inc to Potentially Rebound After Falling 1.71% Yesterday

Agenus Inc (NASDAQ:AGEN) traded in a range yesterday that spanned from a low of $3.94 to a high of $4.17. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $4.20 on...

AGEN : 3.99 (+2.31%)
Is the Options Market Predicting a Spike in Agenus (AGEN) Stock?

Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.

AGEN : 3.99 (+2.31%)
Moving Average Crossover Alert: Agenus

Agenus Inc. (AGEN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

AGEN : 3.99 (+2.31%)
Catalyst's (CPRX) Q3 Earnings Beat Estimates, Sales Miss

Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2019.

AGEN : 3.99 (+2.31%)
ANIK : 45.60 (-0.63%)
ALKS : 18.53 (+0.05%)
CPRX : 4.11 (-0.24%)
Agenus to Host R&D Day November 15, 2019

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced that it will host an R&D Day on November...

AGEN : 3.99 (+2.31%)
Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat

Amicus (FOLD) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

AGEN : 3.99 (+2.31%)
FOLD : 9.69 (-0.92%)
ALKS : 18.53 (+0.05%)
ANIK : 45.60 (-0.63%)
Biotechs Seek Advancements in the Immuno-Oncology Field for Childhood Brain Tumors

Doctors are working to learn more about brain tumors, ways to prevent them, how to best treat them, and how to provide the best care to people diagnosed with a brain tumor. According to recent articles...

MBRX : 0.90 (-3.23%)
ABBV : 87.35 (-0.73%)
NKTR : 22.17 (-1.12%)
INMD : 45.50 (-3.17%)
AGEN : 3.99 (+2.31%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +0.24 , SEDG +0.89 , THC +0.12 , TER +1.62 , LITE +0.66
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar